Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans

Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans

Item

http://www.wikidata.org/entity/Q28343929

Q28343929

about

pH signaling in human fungal pathogens: a new target for antifungal strategies Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR In vitro and in vivo activities of ruthenium(II) phosphine/diimine/picolinate complexes (SCAR) against Mycobacterium tuberculosis Antifungal activities of tacrolimus and azole agents against the eleven currently accepted Malassezia species Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis.Calcineurin governs thermotolerance and virulence of Cryptococcus gattii.Chemosensitization of fluconazole resistance in Saccharomyces cerevisiae and pathogenic fungi by a D-octapeptide derivative.Stimulation of chitin synthesis rescues Candida albicans from echinocandins.Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans.Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis.Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins.Signal transduction cascades regulating fungal development and virulence.Calcineurin is essential for survival during membrane stress in Candida albicans.Essential role of calcineurin in response to endoplasmic reticulum stress.Application of caspofungin in China compared with amphotericin B and fluconazole.Regulatory circuitry governing fungal development, drug resistance, and disease.Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections.A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis The Crz1/Sp1 transcription factor of Cryptococcus neoformans is activated by calcineurin and regulates cell wall integrity.Characterization of the bafilomycin biosynthetic gene cluster from Streptomyces lohii.Systems-level antimicrobial drug and drug synergy discovery.Multiple signaling pathways regulate yeast cell death during the response to mating pheromones.Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo.Caspofungin: first approved agent in a new class of antifungals.The Cryptococcus neoformans MAP kinase Mpk1 regulates cell integrity in response to antifungal drugs and loss of calcineurin function A flucytosine-responsive Mbp1/Swi4-like protein, Mbs1, plays pleiotropic roles in antifungal drug resistance, stress response, and virulence of Cryptococcus neoformans.Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature Mitogen-activated protein kinase stimulation of Ca(2+) signaling is required for survival of endoplasmic reticulum stress in yeast.In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.The pharmacology and clinical use of caspofungin.Nonapoptotic death of Saccharomyces cerevisiae cells that is stimulated by Hsp90 and inhibited by calcineurin and Cmk2 in response to endoplasmic reticulum stresses.Combination therapeutic approaches for the management of invasive aspergillosis in organ transplant recipients.Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.Kch1 family proteins mediate essential responses to endoplasmic reticulum stresses in the yeasts Saccharomyces cerevisiae and Candida albicans.In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.Antifungal adjuvants: Preserving and extending the antifungal arsenal

P2860

Q26830123-89B6B9AB-AA0A-49AE-862B-AABBE4DCC5B0 Q28361576-1C5479D3-C12D-42BF-847D-C94F20C5F909 Q28533382-A176A313-0140-40C3-9D0C-714C580D2FB3 Q28769637-200F2624-44C8-455C-841C-8FD7765DB546 Q30438524-414645C8-E4E9-4E9A-B8C5-CC111CDBB652 Q30441628-13A8D7AE-F59A-4BF0-B54B-936FD1C27939 Q30536858-4A40623D-1FB1-4856-BFA8-319892E313D8 Q33200348-26479E45-CD57-4039-B5A3-A1A5A7CD5222 Q33326983-863260E4-C51A-4754-8AC3-F48069E51363 Q33593689-3996D7BE-43C4-4305-A945-DDF4CBAFD413 Q33805542-DFB8E8F0-B578-4159-9E5C-E80BF02FA7EB Q33883762-0523EC17-EDA6-434E-A294-6432D78B9EC9 Q34010291-1615596A-30F5-4319-B563-A4A4DA45F0A9 Q34085830-62E1242C-749F-4A1C-AE1C-809B0D3DEBC2 Q34087957-403D916A-2BB9-4B47-9CFD-21B6F8E59029 Q34182814-4A0DCAAE-5F3A-43E3-A15E-0FE79CF62B73 Q34190284-C0D9CB1E-AA5F-44F6-AC3D-EAD1EFCE2C96 Q34399223-7DD2A59A-E136-47A8-AD8C-C6AD77B885A3 Q34481664-43D62884-F055-41D4-A22F-57E17BB54578 Q34513852-641FF160-BD68-431F-8B57-000FA9688C62 Q34516564-7EA80E28-074E-468B-ACA6-9E7DAFAB80F7 Q34567302-218B5ACE-BD96-4B59-9AE6-5864D9D33239 Q34626969-14B4EDE0-E2E5-45D8-8F25-24A598338F74 Q34886111-17BE23B3-D707-4D5C-93BA-F0F082C0663B Q35092521-4A86B686-F6AA-47AD-B74E-C09C8484BF13 Q35124726-A3CE9077-193E-4E5F-950A-0DC9970F2E1B Q35128586-067FD1FD-A379-4286-AADD-847ACD9F79CC Q35666161-CC340F4E-6AB4-435E-8106-1246AC103D9A Q35959484-423B766B-5939-40A4-A86B-75DF261895F8 Q36125241-561A62C2-776D-4B5D-B555-B04DAEE17B90 Q36425093-97284F8B-F49D-49AD-8FE3-0D16647DBF0E Q36626518-018ADF81-62AF-4A06-9071-8AA845AEA36F Q36788428-D68E3617-4CE2-40C6-AE26-0BA76BA948BE Q36994306-4D8FCB6A-91D8-4799-9C2B-2882B2474EF6 Q37078394-D7CC2635-CBD8-4DE0-B147-16C4A943926E Q37122826-36CB1767-E286-4217-B6DB-D80C43395D5F Q37274705-D233CACD-B554-435B-AF77-5465D8790B40 Q37349001-46E32F1D-8BA4-44A1-AE8F-311838282B8C Q37625139-B6B224B2-A83E-4EB7-AEC9-0CEA8E224598 Q37705308-267CEB2C-5FEC-42CE-9254-DDBF06D56BD6

P2860

Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans

Item

http://www.wikidata.org/entity/Q28343929

description

2000 nî lūn-bûn

@nan

2000 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի մարտին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu